RegeneRx’s New Scientific Publication Reports Results of RGN-259 in P-III Study for the Treatment of Neurotrophic Keratopathy
Shots:
- The P-III clinical trial evaluates the safety & efficacy of ReGenTree’s (joint venture between RegeneRx Biopharmaceuticals & HLB Therapeutics) RGN-259 eyedrops (n=10) vs PBO (n=8) in patients with Neurotrophic Keratopathy (NK)
- The results from the study demonstrated healing of persistent epithelial defects in patients with Stages 2 & 3 NK along with statistically significant healing at day 43. The efficacy data depicted complete healing after 4wks. in 6 of 10 vs 1 of 8 patients
- RGN-259 is a sterile preservative-free, eye drop which reduces damage & improves healing for the treatment of ophthalmic indications incl. dry eye syndrome & neurotrophic keratopathy
Ref: PRNewswire | Image: RegeneRx
Related News:- Novartis Announces Spin-Off of Alcon Eye Care Business on April 9- 2019
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
